Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free SXTC Stock Alerts

China SXT Pharmaceuticals (SXTC) Competitors

China SXT Pharmaceuticals logo
$2.39 +0.20 (+9.13%)
As of 10:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SXTC vs. LIAN, REVB, GRI, XRTX, and SILO

Should you buy China SXT Pharmaceuticals stock or one of its competitors? China SXT Pharmaceuticals's main competitors and comparable companies include LianBio (LIAN), Revelation Biosciences (REVB), GRI Bio (GRI), XORTX Therapeutics (XRTX), and Silo Pharma (SILO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does China SXT Pharmaceuticals compare to LianBio?

China SXT Pharmaceuticals (NASDAQ:SXTC) and LianBio (NASDAQ:LIAN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, China SXT Pharmaceuticals had 1 more articles in the media than LianBio. MarketBeat recorded 1 mentions for China SXT Pharmaceuticals and 0 mentions for LianBio. China SXT Pharmaceuticals' average media sentiment score of 1.89 beat LianBio's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Very Positive
LianBio Neutral

China SXT Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, LianBio has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
LianBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

China SXT Pharmaceuticals' return on equity of 0.00% beat LianBio's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
LianBio N/A -33.17%-30.19%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

China SXT Pharmaceuticals has higher revenue and earnings than LianBio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.01-$6.20MN/AN/A
LianBioN/AN/A-$110.29M-$0.81N/A

Summary

China SXT Pharmaceuticals beats LianBio on 8 of the 10 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Revelation Biosciences?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Revelation Biosciences (NASDAQ:REVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

China SXT Pharmaceuticals' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Revelation Biosciences N/A -100.19%-82.72%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

China SXT Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Revelation Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

China SXT Pharmaceuticals has higher revenue and earnings than Revelation Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.01-$6.20MN/AN/A
Revelation BiosciencesN/AN/A-$8.91M-$12.31N/A

In the previous week, Revelation Biosciences had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 2 mentions for Revelation Biosciences and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.89 beat Revelation Biosciences' score of 1.44 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Very Positive
Revelation Biosciences Positive

Summary

China SXT Pharmaceuticals beats Revelation Biosciences on 6 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to GRI Bio?

China SXT Pharmaceuticals (NASDAQ:SXTC) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 8.7% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

China SXT Pharmaceuticals has higher revenue and earnings than GRI Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.01-$6.20MN/AN/A
GRI BioN/AN/A-$11.96M-$38.37N/A

GRI Bio has a consensus target price of $21.00, suggesting a potential upside of 1,066.67%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
GRI Bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

China SXT Pharmaceuticals' return on equity of 0.00% beat GRI Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
GRI Bio N/A -134.03%-106.83%

China SXT Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

In the previous week, GRI Bio had 9 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 10 mentions for GRI Bio and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.89 beat GRI Bio's score of 0.81 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Very Positive
GRI Bio Positive

Summary

China SXT Pharmaceuticals and GRI Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to XORTX Therapeutics?

China SXT Pharmaceuticals (NASDAQ:SXTC) and XORTX Therapeutics (NASDAQ:XRTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, XORTX Therapeutics had 4 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for XORTX Therapeutics and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.89 beat XORTX Therapeutics' score of 1.01 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Very Positive
XORTX Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of XORTX Therapeutics shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

XORTX Therapeutics has lower revenue, but higher earnings than China SXT Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.01-$6.20MN/AN/A
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A

China SXT Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, XORTX Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

China SXT Pharmaceuticals' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
XORTX Therapeutics N/A -137.85%-108.16%

Summary

China SXT Pharmaceuticals beats XORTX Therapeutics on 6 of the 9 factors compared between the two stocks.

How does China SXT Pharmaceuticals compare to Silo Pharma?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Silo Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Silo Pharma has lower revenue, but higher earnings than China SXT Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.14M1.01-$6.20MN/AN/A
Silo Pharma$70K42.36-$4.23M-$4.36N/A

China SXT Pharmaceuticals has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. China SXT Pharmaceuticals' return on equity of 0.00% beat Silo Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Silo Pharma -6,726.39%-81.75%-66.35%

5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

China SXT Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Silo Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Silo Pharma had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.89 beat Silo Pharma's score of 1.22 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
China SXT Pharmaceuticals Very Positive
Silo Pharma Positive

Summary

China SXT Pharmaceuticals beats Silo Pharma on 7 of the 11 factors compared between the two stocks.

Get China SXT Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTC vs. The Competition

Export
MetricChina SXT PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.15M$12.58B$7.25B$15.16B
Dividend YieldN/A2.64%2.57%12.31%
P/E RatioN/A794.78273.9225.59
Price / Sales1.01755.16640.3189.26
Price / CashN/A85.4276.4050.90
Price / Book0.0010.4810.446.29
Net Income-$6.20M$2.83B$3.49B$358.07M
7 Day Performance23.83%-0.10%0.31%0.35%
1 Month Performance-36.27%1.76%-0.32%-3.12%
1 Year Performance-99.99%4.86%22.44%6.93%

China SXT Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTC
China SXT Pharmaceuticals
1.1536 of 5 stars		$2.39
+9.1%		N/A-100.0%$1.15M$1.14MN/A90
LIAN
LianBio
N/A$0.04
-3.6%		N/A+10.4%$4.07MN/AN/A110
REVB
Revelation Biosciences
1.4048 of 5 stars		$1.01
flat		N/A-85.4%$4.02MN/AN/A10
GRI
GRI Bio
3.415 of 5 stars		$1.80
-10.0%		$32.00
+1,677.8%		-96.7%$3.94MN/AN/A1
XRTX
XORTX Therapeutics
1.0345 of 5 stars		$2.16
-5.3%		N/A-58.1%$3.93MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTC) was last updated on 9/17/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel